Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- EGRX
- Price
- 0.25
- Stock movement up
- +- (0.00%)
- Company name
- Eagle Pharmaceuticals Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Drug Manufacturers - Specialty & Generic
- Market cap
- 3.29M
- Ent value
- 140.72M
- Price/Sales
- 0.01
- Price/Book
- 0.01
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -2.63%
- Trailing P/E
- 0.21
- Forward P/E
- -
- PEG
- -
- EPS growth
- -3.53%
- 1 year return (CAGR)
- -78.81%
- 3 year return (CAGR)
- -80.12%
- 5 year return (CAGR)
- -65.27%
- 10 year return (CAGR)
- -42.37%
Last updated: 2026-02-20
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
EGRX does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | 0.21 |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | 0.07 |
| EV to EBITDA | 2.88 |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 0.01 |
| Price to Book | 0.01 |
| EV to Sales | 0.55 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 13.16M |
| EPS (TTM) | 1.18 |
| FCF per share (TTM) | -0.71 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 257.55M |
| Gross profit (TTM) | 179.88M |
| Operating income (TTM) | 23.65M |
| Net income (TTM) | 15.57M |
| EPS (TTM) | 1.18 |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | 69.84% |
| Operating margin (TTM) | 9.18% |
| Profit margin (TTM) | 6.04% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 15.35M |
| Net receivables | 116.28M |
| Total current assets | 187.25M |
| Goodwill | 45.03M |
| Intangible assets | 107.41M |
| Property, plant and equipment | 7.83M |
| Total assets | 404.82M |
| Accounts payable | 15.84M |
| Short/Current long term debt | 71.61M |
| Total current liabilities | 86.63M |
| Total liabilities | 152.78M |
| Shareholder's equity | 252.04M |
| Net tangible assets | 99.60M |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -9.32M |
| Capital expenditures (TTM) | 84.00K |
| Free cash flow (TTM) | -9.39M |
| Dividends paid (TTM) | 247.00K |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | 6.18% |
| Return on Assets | 3.85% |
| Return on Invested Capital | 4.83% |
| Cash Return on Invested Capital | -2.91% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.25 |
| Daily high | 0.25 |
| Daily low | 0.25 |
| Daily Volume | 0K |
| All-time high | 100.56 |
| 1y analyst estimate | 17.00 |
| Beta | 0.95 |
| EPS (TTM) | 1.18 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 9 Mar 2026 |
Downside potential
Loading...
Downside potential data
| EGRX | S&P500 | |
| Current price drop from All-time high | -99.75% | -1.98% |
| Highest price drop | -99.90% | -56.47% |
| Date of highest drop | 16 Dec 2025 | 9 Mar 2009 |
| Avg drop from high | -52.99% | -10.84% |
| Avg time to new high | 57 days | 12 days |
| Max time to new high | 2647 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
3.29M
Marketcap category
Small-cap
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on manufacturing, developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company's product portfolio offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. It also produces PEMFEXY, a ready-to-dilute liquid form of pemetrexed injection for non-small cell lung cancer and mesothelioma. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an anti-toxin agent in Phase 2 development for the treatment of severe pneumonia in combination with traditional antibacterial drugs. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat cancer. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.
Employees
134
Website
Investor relations
-
SEC filings
CEO
Scott L. Tarriff
Country
USA
City
Woodcliff Lake
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page